Processing

Please wait...

Settings

Settings

Goto Application

1. CA2911938 - VACCINE COMPOSITIONS COMPRISING SP OIL AND P-CLASS IMMUNOSTIMULATORY OLIGONUCLEOTIDES

Office
Canada
Application Number 2911938
Application Date 12.05.2014
Publication Number 2911938
Publication Date 20.11.2014
Grant Number
Grant Date 16.07.2019
Publication Kind C
IPC
A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/008
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
002Protozoa antigens
008Leishmania antigens
A61K 39/27
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
27Equine rhinopneumonitis virus
CPC
A61K 39/008
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
002Protozoa antigens
008Leishmania antigens
A61K 39/27
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
27Equine rhinopneumonitis virus
A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 2039/55561
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55561CpG containing adjuvants; Oligonucleotide containing adjuvants
A61K 2039/55577
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55577Saponins; Quil A; QS21; ISCOMS
C12N 2710/16034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
16011Herpesviridae
16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants ZOETIS SERVICES LLC
Inventors DOMINOWSKI, PAUL JOSEPH
RAI, SHARATH K.
SLY, LAUREL MARY
COOK, COREY PATRICK
MWANGI, DUNCAN
FOSS, DENNIS L.
KREBS, RICHARD LEE
Priority Data 61/823,189 14.05.2013 US
Title
(EN) VACCINE COMPOSITIONS COMPRISING SP OIL AND P-CLASS IMMUNOSTIMULATORY OLIGONUCLEOTIDES
(FR) COMPOSITIONS DE VACCIN RENFERMANT DE L'HUILE SP ET DES OLIGONUCLEOTIDES IMMUNOSTIMULATEURS DE CLASSE P
Abstract
(EN) The invention provides a vaccine composition comprising an antigen component and an adjuvant component, wherein the adjuvant component comprises a P-class immunostimulatory oligonucleotide and either a combination of a saponin and a sterol; or an oily phase comprising an oil and, optionally, one or more emulsifiers, said oily phase comprising 2-20% v/v of the vaccine composition, wherein said antigen component is an EHV antigen or a Leishmania antigen.
(FR) La présente invention concerne une composition de vaccin comprenant une composante antigène et une composante adjuvant, la composant adjuvant comprenant un oligonucléotide immunostimulateur de classe P et soit une association de saponine et d'un stérol; soit une phase huileuse comprenant une huile et, facultativement, un ou plusieurs émulsifiants, ladite phase huileuse constituant 2 à 20 % v/v de la composition de vaccin, ladite composante antigène étant un antigène EHV ou un antigène Leishmania.